🎁 Black Friday: up to 50% off of annual plans
NeoImmuneTech, Inc. (KOSDAQ:950220)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,410.00
-75.00 (-5.05%)
Nov 20, 2026, 3:30 PM KST

NeoImmuneTech Statistics

Total Valuation

NeoImmuneTech has a market cap or net worth of KRW 139.40 billion. The enterprise value is 112.86 billion.

Market Cap139.40B
Enterprise Value 112.86B

Important Dates

The next estimated earnings date is Friday, March 19, 2027.

Earnings Date Mar 19, 2027
Ex-Dividend Date n/a

Share Statistics

NeoImmuneTech has 98.87 million shares outstanding. The number of shares has increased by 220.31% in one year.

Current Share Class n/a
Shares Outstanding 98.87M
Shares Change (YoY) +220.31%
Shares Change (QoQ) -6.42%
Owned by Insiders (%) 0.05%
Owned by Institutions (%) n/a
Float 92.13M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 21.11
PB Ratio 3.00
P/TBV Ratio 5.55
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 17.09
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 2.01, with a Debt / Equity ratio of 0.25.

Current Ratio 2.01
Quick Ratio 1.89
Debt / Equity 0.25
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -8.11

Financial Efficiency

Return on equity (ROE) is -40.77% and return on invested capital (ROIC) is -19.08%.

Return on Equity (ROE) -40.77%
Return on Assets (ROA) -16.41%
Return on Invested Capital (ROIC) -19.08%
Return on Capital Employed (ROCE) -43.08%
Weighted Average Cost of Capital (WACC) 8.29%
Revenue Per Employee 126.97M
Profits Per Employee -439.34M
Employee Count 42
Asset Turnover 0.08
Inventory Turnover n/a

Taxes

In the past 12 months, NeoImmuneTech has paid 37.43 million in taxes.

Income Tax 37.43M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -49.46% in the last 52 weeks. The beta is 0.60, so NeoImmuneTech's price volatility has been lower than the market average.

Beta (5Y) 0.60
52-Week Price Change -49.46%
50-Day Moving Average 1,777.40
200-Day Moving Average 2,238.96
Relative Strength Index (RSI) 30.29
Average Volume (20 Days) 103,336

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, NeoImmuneTech had revenue of KRW 6.60 billion and -22.85 billion in losses. Loss per share was -179.07.

Revenue6.60B
Gross Profit 4.40B
Operating Income -20.63B
Pretax Income -22.81B
Net Income -22.85B
EBITDA -17.77B
EBIT -20.63B
Loss Per Share -179.07
Full Income Statement

Balance Sheet

The company has 38.11 billion in cash and 11.57 billion in debt, with a net cash position of 26.55 billion or 268.51 per share.

Cash & Cash Equivalents 38.11B
Total Debt 11.57B
Net Cash 26.55B
Net Cash Per Share 268.51
Equity (Book Value) 46.50B
Book Value Per Share 1,343.31
Working Capital 21.09B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -17.22 billion and capital expenditures -91.78 million, giving a free cash flow of -17.32 billion.

Operating Cash Flow -17.22B
Capital Expenditures -91.78M
Depreciation & Amortization 2.86B
Net Borrowing -750.94M
Free Cash Flow -17.32B
FCF Per Share -175.15
Full Cash Flow Statement

Margins

Gross Margin 66.61%
Operating Margin -312.48%
Pretax Margin -345.46%
Profit Margin n/a
EBITDA Margin -269.19%
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

NeoImmuneTech does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -220.31%
Shareholder Yield -220.31%
Earnings Yield -12.70%
FCF Yield -12.42%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a
Graham Formula Value n/a
Graham Formula Upside n/a

Stock Splits

The last stock split was on May 15, 2026. It was a reverse split with a ratio of 0.2.

Last Split Date May 15, 2026
Split Type Reverse
Split Ratio 0.2

Scores

NeoImmuneTech has an Altman Z-Score of -0.59 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -0.59
Piotroski F-Score 2